The Mexican Social Security Institute (IMSS) has initiated a collaboration with the American Chamber of Commerce of Mexico (AmCham) to boost clinical research within public hospitals, a development that promises to enhance healthcare accessibility for millions of citizens. With an anticipated investment exceeding 766 million pesos (approximately $44 million), this partnership aims to establish a robust network for pharmaceutical clinical trials through IMSS’s extensive hospital infrastructure. By 2030, this initiative hopes to expand the role of public healthcare in research, traditionally dominated by private institutions.
In this collaboration, several prominent pharmaceutical companies, including Amgen, AstraZeneca, and Roche, will join forces with IMSS, emphasizing the institute’s capability to manage clinical trials effectively. IMSS Director General Zoé Robledo emphasized that this is not about competing with private hospitals but rather offering an opportunity to explore more avenues in clinical research. Currently, about 70% of trials are conducted in private centers, while IMSS holds unique advantages, with a network of over 1,800 facilities serving approximately 70 million beneficiaries.
This effort is part of a larger strategy to incorporate scientific research into everyday healthcare, specifically targeting prevalent and complex medical conditions such as diabetes, hypertension, and cancer. The initiative will also focus on training 729 IMSS researchers to enhance the institution’s research capacity. This endeavor stands as a significant step toward making quality clinical research more accessible and beneficial for the Mexican populace, ultimately aiming to translate research findings into better patient care. As the project unfolds, IMSS is already progressing with clinical studies, including ongoing research for Sjögren’s syndrome and planning further studies on irritable bowel syndrome.